Blood stage malaria parasites causing a mild and self limited infection in mice have been obtained with either radiation or chemical mutagenesis showing the possibility of developing an attenuated malaria vaccine. Targeted disruption of plasmepsin-4 (pm4) or the merozoite surface protein-7 (msp7) genes also induces a virulence-attenuated phenotype in terms of absence of experimental cerebral malaria (ECM), delayed increase of parasitemia and reduced mortality rate. The decrease in virulence in parasites lacking either pm4 or msp7 is however incomplete and dependent on the parasite and mouse strain combination. The sequential disruption of both genes induced remarkable virulence-attenuated blood-stage parasites characterized by a self-resolving infection with low levels of parasitemia and no ECM. Furthermore, convalescent mice were protected against the challenge with P. berghei or P. yoelii parasites for several months. These observations provide a proof-of-concept step for the development of human malaria vaccines based on genetically attenuated blood-stage parasites.
Blood stage malaria parasites causing a mild and self limited infection in mice have been obtained with either radiation or chemical mutagenesis showing the possibility of developing an attenuated malaria vaccine. Targeted disruption of plasmepsin-4 (pm4) or the merozoite surface protein-7 (msp7) genes also induces a virulence-attenuated phenotype in terms of absence of experimental cerebral malaria (ECM), delayed increase of parasitemia and reduced mortality rate. The decrease in virulence in parasites lacking either pm4 or msp7 is however incomplete and dependent on the parasite and mouse strain combination. The sequential disruption of both genes induced remarkable virulence-attenuated blood-stage parasites characterized by a self-resolving infection with low levels of parasitemia and no ECM. Furthermore, convalescent mice were protected against the challenge with P. berghei or P. yoelii parasites for several months. These observations provide a proof-of-concept step for the development of humanmalaria vaccines based on genetically attenuated blood-stage parasites.
Plasmodium falciparuminfection causes in non immune individuals a number of life
threatening complications including metabolic acidosis, respiratory distress, severe
anemia and neurological syndrome known as cerebral malaria that account for the death of
about one million children every year in malaria endemic regions. The key pathological
features of severe malaria include the obstruction of microvascular districts by
parasitized erythrocytes, the rapid expansion of the parasite mass, the destruction of
infected erythrocytes and the activation of inflammatory processes123. The sequestration of parasitized erythrocytes to different vascular districts plays
a major role in determining the organs and the tissues affected in some situations such
as the brain in cerebral malaria and the placenta in pregnant women45678. Members of the highly polymorphic P. falciparum
erythrocyte membrane protein 1 family have been shown to play a critical function in
this process91011. The role of other factors such as the parasite
mass and the growth rate in determining the pathology and the severity of the infection
is less clear. Although gene targeting technology has dramatically enhanced our
molecular understanding of P. falciparum12131415 blood stage
life cycle in terms of its metabolism, growth rate and erythrocyte invasion, the role of
individual genes in shaping parasite virulence is much less clear because of the lack of
suitable experimental models of human malaria161718192021. The
infection caused by Plasmodium berghei in rodents partially mimics humanmalaria
and is regarded as a valuable in vivo model to study parasite induced pathology
and the development of protective immunity. In P. berghei, similarly to what has
been observed for P. falciparum, disruption of important blood-stage transcribed
genes is very difficult to accomplish22232425. Only a small number
of blood-stage genes, including msp7 and pm4, have been disrupted in both
P. berghei and P. falciparum allowing the analysis of how impairment
of in vitro growth translates into a virulence change of rodent malaria in
vivo23262728.In P. falciparum the disruption of the msp7 gene, a member of a multigene
family comprising msp7 and five msp7-related protein (MSRP) genes29, significantly impairs merozoites invasion of erythrocytes27. In the rodent malaria parasitesP. berghei, that contains a
single msp7 gene and two MSRP genes2330, targeting of
msp7 does not induce a dramatic in
vivo phenotype. These parasites show a more pronounced reticulocyte-tropic cell
preference but only a mild growth delay can be observed in infected mice23. In P.
falciparum the disruption of pm4, the aspartic protease that functions in
the lysosomal compartment and contributes to hemoglobin digestion, causes only a modest
decrease in asexual blood-stage growth rate26. Similarly only a modest
retardation in the asexual blood-stage growth rate both in vitro and in
vivo is observed in P. berghei parasites lacking pm428. Surprising this apparently insignificant growth impairment translates
into a dramatic decrease in in vivo virulence. These parasites failed to induce
experimental cerebral malaria (ECM) in ECM-susceptible mice and ECM-resistant mice were
able to clear infection. Furthermore, after a single infection all convalescent mice
were protected against subsequent challenge with lethal parasites. To further
investigate the relationship linking growth rate and virulence we studied the phenotype
of Δmsp7 parasites in terms of ability to induce ECM and development of
parasitemia in a number of mouse strains with different genetic backgrounds. We have
also generated parasites that lack both msp7 and pm4 to evaluate if the
combined gene disruption had an additive effect on the attenuation of virulence.
Results
Development of MSP7 and PM4/MSP7 knockout P. berghei
parasites
A parasite strain lacking the msp7 gene has been already developed few
years ago, however because of the need of appropriate controls we generated new
parasites clones in which we have disrupted the msp7 gene in both pbwt
(Δmsp7 cl7 and Δmsp7 cl8) and pbwt+ genetic
backgrounds2831 (Δmsp7+) (Figure 1A). The pbwt+ parasites express a
GFP-luciferase fusion protein under the transcriptional control of the
ama-1 promoter that allows the monitoring of parasite load,
distribution and patterns of schizont sequestration in live mice by real time
in vivo imaging. We confirmed the disruption of the msp7 gene
and the correct integration of the replacement construct in all transgenic
clones by genomic diagnostic PCR (Figure 1B). Reverse
transcription (RT)-PCR (Figure 1C) and immunofluorescence
analysis of mixed blood-stage parasites (Figure 1D), from
mice with high parasitemia, confirmed the absence of msp7 transcript and
protein in Δmsp7 clones. Double pm4 and msp7 knock-out
parasite clones (Δpm4/Δmsp7 cl4 and Δpm4/Δmsp7
cl12) were generated from two independent transfection experiments, using a
construct designed to target the msp7 gene in the parasite line
Δpm4 cl6 in which the pm4 gene had been previously deleted28 (Supplemental Figure 1A). Correct deletion
of the msp7 gene and integration of the replacement construct in the
double knock-out parasite was confirmed by genomic diagnostic PCR (Supplemental Figure 1B). The lack of both msp7 and pm4
transcripts was showed by RT-PCR analysis from mixed blood-stage parasites (Supplemental Figure 1C).
Figure 1
Targeted gene disruption of the
(a) Schematic representation of the replacement vector pRSmsp7-tgdhfr/ts (i)
and the msp7 locus (ii). The wild-type msp7 locus is targeted
with a linear fragment containing the 5′ and 3′ UTRs
(striped bars) of the msp7 coding sequence (solid black bars) and the
selectable marker tgdhfr/ts (gray box). The integration of the
construct by double crossover recombination results in the replacement of
the msp7 gene with the tgdhfr/ts drug selectable marker (iii).
The position and orientation of primers used for diagnostic PCR are
indicated with arrow heads. (b) Diagnostic PCR experiments to show the
correct integration of the construct. The primer pairs 1+2 amplified a
fragment of 1008 bp demonstrating the presence of the intact msp7
locus in pbwt parasites, whereas no product was obtained with genomic DNA
from Δmsp7 parasites clones. The primer pairs 3+4 and 5+6 amplified
a product of 558 bp and 452 bp respectively only in the genomic DNA from
Δmsp7 parasites demonstrating the correct integration of the
construct. (c) In Δmsp7 parasites RT-PCR analysis failed to amplify
the msp7 gene transcript from RNA of blood stage P. berghei
parasites. As a positive control specific primers were used to
amplify the tub transcript. (d) Light- and dark- field
immunofluorescence microphotographs of pbwt and Δmsp7 parasites
analyzed by a polyclonal antibody directed against recombinant MSP7 protein.
Bar indicates 50 µm.
Virulence phenotype of Δmsp7 and Δpm4/Δmsp7
parasites
We have investigated in different mouse strains the virulence of Δmsp7
parasites in terms of development of peak parasitemia, mortality rate and
ability to induce ECM. Mouse strains that are known to be either resistant
(BALB/c) or susceptible (C57BL/6 and CD1) to ECM were infected with increasing
number of parasites. We observed in Δmsp7 infected BALB/c mice only a
mild delay in the parasite growth rate during the initial phase of in
vivo infection irrespectively of the injection route (intravenous i.v.
versus intraperitoneal i.p.) (Figure 2A and 2B). The mice
progressively developed a high parasitemia and died during the third week post
infection similarly to pbwt-infected mice in agreement with previous
reports23. The Δmsp7 parasites did not show in
vivo anomalies in the process of cell maturation and schizont
development (not shown). We also extended the characterization of the virulence
phenotype of Δmsp7 parasites to ECM susceptible C57BL/6 mice. In this
parasite-mouse strain combination, Δmsp7 parasites showed a significant
reduction (p<0.001) on the growth rate up to day 12 post infection and
notably failed to induce signs and symptoms of ECM (Figure 3A,
3C and Supplemental Figure 2A). These mice showed
a prolonged course of infection with increasing parasitemia and died during the
fourth week post infection with a peak parasitemia reaching 70% (Figure 3A and 3B). On the contrary all pbwt-infected mice died at
around day 8 post-infection when the parasitemia was still low (around 20%)
developing a typical ECM pathology. Mice inoculated with 105 or
106 Δmsp7 parasites consistently failed to develop
ECM suggesting that the absence of ECM in Δmsp7 infected mice did not
depend on the level of parasitemia. The virulence attenuated phenotype
Δmsp7 parasites varied with the mouse strain used. A substantial
fraction of infected Δmsp7 CD1mice (about 60%) died within 10 days
post-infection with signs and symptoms of ECM and with a parasitemia below 15%
while the others mice died later of severe anemia (Figure
3). The parasites in which both pm4 and msp7 genes had
been disrupted showed irrespective of the mouse strain utilized a remarkable
decrease in the virulence that combined the individual phenotypes of the
msp7 and pm4 knockout parasites. In BALB/c mice the growth
rate of Δpm4/Δmsp7 parasites was significantly delayed compared
to Δmsp7 parasites up to 12 days post-infection with a peak of
parasitemia at around day 21 that was rapidly cleared from the blood resulting
in undetectable parasitemia by microscopic analysis by day 30 (Figure 2A and 2B). While C57BL/6 mice infected with single
Δpm4 and Δmsp7 parasites did not show any sign of ECM but died
later of severe anemia, most of the mice infected with
Δpm4/Δmsp7 were able to control and completely clear the
parasites from the blood (Figure 3A). Notably
Δpm4/Δmsp7 parasites induced in C57BL/6 mice a low peak
parasitemia that reached a maximum of 10% at day 12 post-infection and by day 25
the infection became undetectable by microscopic analysis (Figure
3A). On the contrary single pm4 and msp7 knock out
parasites though failing to cause ECM in C57BL/6 mice consistently induced high
levels (up to 70%) of parasitemia. A significant increased on the survival rate
was observed in Δpm4/Δmsp7 infected CD1mice. The majority of
the CD1mice (about 60%) showed a decreased peak of parasitemia, survived the
infection and were able to clear the infected red blood cells (iRBCs) by day 30
post-injection (Figure 3). The remaining animals died
after day 13 post-infection manly of severe anemia (Figure
3). All these results indicated that virulence phenotype of
Δpm4/Δmsp7 parasites was dramatically reduced compared to wild
type parasites and combines traits of single pm4 or msp7 knock-out
parasites.
Figure 2
Time course of Δmsp7 and Δpm4/Δmsp7 infections in
BALB/c and nude mice.
The percentage of survival (first column) and the time course of parasitemia
(second column) are shown. BALB/c mice were inoculated either i.p. (a) (n =
10 per group) or i.v. (b) (n = 10 per group) with 107 and 50
infected erythrocytes respectively using Δmsp7,
Δpm4/Δmsp7 and pbwt parasites. Parasitemia was daily
evaluated by Giemsa stained thin blood smears. Mice infected with pbwt and
Δmsp7 parasites succumbed infection while animals infected with
Δpm4/Δmsp7 survived and cleared the infection. (c) Nude mice
(n = 10 per group) were injected i.p. with 107 pbwt or
Δpm4/Δmsp7 parasites. In this parasite-mouse strain
combination while most of pbwt injected mice died of high parasitemia at
around day 20, Δpm4/Δmsp7 injected mice showed very low
levels of parasitemia in the first three weeks post-infection and succumbed
to the infection only after two months post-injection. These data are
representative of 2 two independent experiments. For survival curve log rank
test: *** p<0.001. For parasitemia Mann-Whitney test between
transgenic and wild-type parasites: *** p<0.001.
Figure 3
Time course of Δmsp7 and Δpm4/Δmsp7 infections in
C57BL/6 and CD1 mice.
The graphs show the level of parasitemia (a), the percentage of survival (b)
and the body temperature (c) in C57BL/6 mice (left panel) and CD1 mice
(right panel) injected i.p. with 105 pbwt, Δmsp7 and
Δpm4/Δmsp7 parasites. C57BL/6 mice (n = 10 per group)
infected with pbwt parasites died approximately 6–8 days post
infection showing low level of parasitemia (below 20%) and signs of ECM
accompanied with hypothermia. On the contrary mice infected with
Δmsp7 parasites did not show signs of ECM, survived up to the forth
week post infection and died shortly afterwards with very high parasitemia.
Mice infected with Δpm4/Δmsp7 did not show signs of ECM,
develop lower levels of parasitemia compared to pbwt and Δmsp7
parasites and cleared the infection by day 25. CD1 mice infected with pbwt
parasites died between day 8 to 12 post infection with a parasitemia of
about 40% showing sign and symptoms of ECM. Some mice (around 40%) infected
with Δmsp7 parasites did not developed ECM and died within the third
week post infection with high parasitemia. Most of the mice (60%) infected
with Δpm4/Δmsp7 parasites neither did developed neurological
signs nor showed any drop in the body temperature. The animals that survived
infection showed lower levels of parasitemia compared to single
Δmsp7 parasites and cleared the infection by day 30 post infection.
The levels of parasitemia of CD1 mice infected with
Δpm4/Δmsp7 represent the mean ± SD from only the
mice that survived infection. These data are representative of 2 two
independent experiments. For survival curve log rank test: * p<0.05,
*** p<0.001. For parasitemia Mann-Whitney test between transgenic and
wild-type parasites: *** p<0.001.
To further investigate the virulence phenotype of Δpm4/Δmsp7
parasites we infected immunodeficientnude mice that are unable to produce
T-cells. Similarly to BALB/c mice all nude animals injected with pbwt infected
erythrocytes died within 20 days with high parasitemia (Figure
2C). On the contrary, the mice infected with
Δpm4/Δmsp7 survived for more than 50 days and showed low levels
of parasitemia in the first four weeks post infection (Figure
2C). Comparable results were also obtained with NOD/SCIDmice that
carried a combined B- and T-cell immunodeficiency infected with
Δpm4/Δmsp7 parasites (data not shown). These findings support
previous observation showing that T-cell deficient mice are unable to resolve
malaria infections32. CD4+ T cells play an
important role during the early stages of malarial infection, by amplifying the
phagocytic and cell-mediated anti-parasite responses; later in the infection,
they help B cells to produce antibodies, and assist in regulating the innate
response333435.
Analysis of brain pathology in Δmsp7 and
Δpm4/Δmsp7 infected mouse strains
The development of cerebral pathology was analyzed in ECM-susceptible C57BL/6 and
CD1mouse strains. In P. berghei ECM is a well characterized condition
defined as the development of cerebral complications (paralysis, deviation of
the head, convulsions, coma) associated with a drop in body temperature to
< 34°C, at day 6–10 after infection23637. In this study distinct groups of mice were injected i.p.
with 105–106 pbwt, Δmsp7 and
Δpm4/Δmsp7 iRBC. In C57BL/6 mice infected with pbwt we
constantly observed clear neurological symptoms (such as paralysis, deviation of
the head, ataxia, convulsions and coma) associated with a body temperature drop
below 34°C suggesting the insurgence of ECM by day seven post infection
whereas this outcome was never observed in C57BL/6 mice infected with
Δmsp7 or Δpm4/Δmsp7 parasites (Figure
3C). We investigated whether the failure of Δmsp7 parasites
to cause ECM was due to a modified sequestration pattern in vivo. We
analyzed by real time in vivo imaging the distribution of schizonts in
tissues and organs during infection283138. Synchronized
pbwt+ (control line) and Δmsp7+
parasites expressing the luciferase gene under the transcription control of the
schizont-specific ama-1 promoter, injected in CD1mice showed similar
levels of luminescence signal in the lungs, the adipose tissue and the spleen,
thus indicating that the disruption of msp7 did not affect the pattern of
schizonts sequestration in these organs and tissues (Supplemental
Figure 3). Furthermore pbwt+ and
Δmsp7+ parasites showed a similar timing of peak
luciferase activity thus ruling out that the mutant parasite line had a marked
impairment of the cell cycle development (Supplemental Figure
3A). For the bioluminescence analysis we infected groups of C57BL/6
mice with increasing numbers of Δmsp7+ parasites (ranging
from 105–106) and as a control with
105 pbwt+ parasites. At 7 days post infection
we observed in the brains isolated from pbwt+ infected C57BL/6
mice the presence of a strong bioluminescence signal. In contrast, the brain of
Δmsp7+ infected mice irrespectively of the infection
dose and the level of parasitemia showed only a low bioluminescent signal (Figure 4A). Quantitative analysis demonstrated that the
observed difference in bioluminescence of pbwt+ or
Δmsp7+ infected brains was significant (Figure 4B). We also investigate the parasites burden during
the course of infection in others organs. The results revealed that in CD1micepbwt+ parasites are mostly confined in the lungs
(50–75%), in the adipose tissues (15–20%) and in the spleen
(7–15%) at day 5 post-infection without any relevant variation during
the remaining course of infection (Supplemental Figure 2B and
2C). Mice infected with Δmsp7+ parasites showed
the same organ distribution of the bioluminescent signal observed with
pbwt+ parasites. An increase of signal in the adipose tissue
and in the spleen was observed from day 7 onwards post-infection. We could not
carry out a bioluminescence analysis of Δpm4/Δmsp7 parasites
because the luciferase reporter is not present in the parasite line. However, we
previously reported a significant low bioluminescent signal in the C57BL/6 mice
infected with Δpm4+ parasites compared to mice infected
with pbwt+28.
Figure 4
Parasite distribution and blood vessel permeability in C57BL/6 infected
mice.
(a) Representative bioluminescent images of 7 days post infection brains
isolated from C57BL/6 mice infected with either pbwt+ or
Δmsp7+ parasites. The level of parasitemia at the
time the brains were collected is shown as percentage in the photograph
panels. (b) Quantitative analysis of the luminescence signal collected from
the brains of mice infected with either pbwt+ or
Δmsp7+ parasites. Mann-Whitney test: *
p<0.05. (c) Representative digital images of Evans Blue dye extrusion
analysis of brains from pbwt, Δmsp7 and Δmsp7/Δmsp7
infected C57BL/6 mice collected at day 7 post-infection. Only pbwt infected
animals showed a blue staining post infusion with Evans Blue dye that was
nearly absent in the brains of Δmsp7 or Δmsp7/Δmsp7
infected mice. (d) Quantitative analysis of Evans Blue staining of brains
from infected mice (n = 6). Bars represent the mean ± SD from 6
mice. Mann-Whitney test: * p<0.05, ** p<0.01.
To further investigate the development of ECM pathology we examined the integrity
of the blood-brain-barrier (BBB) in infected mice using the Evans Blue dye
extrusion analysis. Only brains from pbwt+ infected animals
showed a clear blue color after perfusion that was almost absent in the brains
of mice infected with Δmsp7 and Δpm4/Δmsp7 (Figure 4C). The quantification of Evans Blue in the brains
extract demonstrated that the infection with Δmsp7 and
Δpm4/Δmsp7 contrary to pbwt caused little damage to the BBB
(Figure 4D).
Δpm4/Δmsp7 infection induces a long lasting protective
immunity in convalescent mice
BALB/c, C57BL/6 and CD1mice that had recovered from infection after a single
injection of Δpm4/Δmsp7 parasites were challenged with pbwt
iRBCs. All mice strains tested were protected against lethal parasite challenge
given at high doses of 107 (Table 1).
Challenged mice showed a short-lasting and low level parasitemia of
<0.01% that was usually cleared within 10 days. The protection elicited
by double knockout parasites was monitored for up to six months after recovery
from the initial infection. We also performed sub-inoculation of blood from
challenged animals into naïve mice (n = 10) and none of them developed
a detectable parasitemia by microscopic analysis. Immunized mice were also
challenged with a different rodent malaria parasite species P. yoelii.
The immune response induced by Δpm4/Δmsp7 parasites protected
the mice also against the heterologous challenge with 104 P.
yoelii iRBCs (Table 1). Challenged mice failed
to develop a detectable infection by microscopic analysis.
Table 1
Protection of Δpm4/Δmsp7 immunized mice against challenged
with P. berghei or P. yoelii.
Mouse strain
Challenge
Time of challenge (days)*
Challenge dose (no. of
parasites)†
No. protected/ challenged
BALB/c
P. berghei (ANKA)
0
107
0/10
BALB/c
“
140
107
14/14
C57BL/6
“
0
107
0/10
C57BL/6
“
190
107
10/10
CD1
“
0
107
0/10
CD1
“
150
107
10/10
BALB/c
P. yoelii (17X)
0
104
0/10
BALB/c
“
30
104
10/10
*Number of days after recovery from first
infection with Δpm4/Δmsp7 parasites.
†Mice were challenged by i.v.
injection of iRBCs
Discussion
We show here that Δmsp7 parasites carrying a disrupted msp7 gene, a
mutation previously reported to cause a modest growth delay, have a virulence
attenuated phenotype. When injected to ECM susceptible C57BL/6 mice Δmsp7
parasites did not induce signs or symptoms of cerebral malaria. At 7 days
post-infection the brains of C57BL/6 mice infected with
Δmsp7+, a parasite line that carries a disrupted
msp7 and expresses the luciferase gene under the transcription control of
the blood stage promoter ama-1, showed a much lower bioluminescent signal
than the brains of pbwt+ infected mice. Furthermore unlike pbwt, the
infection caused by Δmsp7 parasites did not damage the blood brain barrier
(BBB) as demonstrated by the distribution of Evans Blue dye in isolated perfused
brains. The ECM virulence phenotype of Δmsp7 parasites is very similar to
that observed in P. berghei after disrupting the aspartic protease plasmepsin
4 gene28 thought msp7 and pm4 are functionally
unrelated. Parasites lacking either pm4 or msp7 have in common a mild
impairment of the in vivo growth. Possibly a reduction in the parasite growth
rate and hence in the parasite mass as well as in the products of parasite
metabolism may affect both the magnitude and the cytokine profile of the immune
response that in turn determine the occurrence of ECM in susceptible animals. The
recent observation that an imbalance of the anti-inflammatory molecule heme
oxygenase (HO)-1 and its substrate heme (a product of hemoglobin degradation) has a
role in triggering ECM would support this notion39. Indeed evidence
originated from other rodent malaria parasites suggests that growth delay or drug
mediated arrest in the erythrocytic cycle could translate into a significant
reduction of virulence and in the induction of protective immunity. As an example in
P. yoelii the disruption of the gene encoding the purine nucleoside
phosphorylase (PNP) caused a significant reduction of parasite growth and caused a
self limiting infection in vivo40. Similarly, in this parasite
species the disruption of the nucleoside transporter 1 (NT1) generated severely
attenuated blood-stage parasites that conferred complete sterile protection against
subsequent challenges with lethal parasites41. Furthermore,
experiments conducted on drug treated infected mice have shown that timing and
antigen dose play a critical role on the development of an immune response424344. These studies have highlighted the potential importance of
the early events in priming an immune response and also the possible
immunosuppressive effect of high levels of parasitemia. Recent clinical studies
indicate that a strong immune protective response could be elicited by drug cure low
dose of both P. falciparum iRBCs or sporozoites4546. However
a reduced parasite growth rate is not invariably associated with an attenuated ECM
virulence phenotype. P. berghei parasites lacking the elongation factor 1a
(eef1a) have a slow growth rate due to a prolonged G1 phase22, but
induce ECM in susceptible mice. Similarly cathepsin C knockout parasites grow slower
in vivo than the pbwt parental strain but are able to induce ECM
(unpublished observations RS).With respect to the ability to reach sustained levels of parasitemia Δmsp7
and Δpm4 parasites showed distinct phenotypes that varied with the mouse
strain utilized. In BALB/c mice, Δpm4 parasites caused a self-resolving
infection while in ECM susceptible C57BL/6 and CD1mice these parasites though
failing to induce ECM progressively reached a high parasitemia and caused the death
of the animals28. Irrespectively of the mouse strain utilized
Δmsp7 parasites did not cause a self-resolving infection. The number of
parasites in the blood increased progressively until the death of the animals.
Notably the disruption of both pm4 and msp7 genes generated parasites
that compared to the individual knockout strains showed a more dramatic virulence
attenuated phenotype that this time did not vary with the genetic background of the
mice. Irrespective of the mouse strains utilized Δpm4/Δmsp7
parasites generally caused a self-resolving infection that in a substantial fraction
of the infected mice was also characterized by a drastic reduction of the
parasitemia. Furthermore Δpm4/Δmsp7 parasites failed to induce ECM
in susceptible mouse strains similar to what we observed in individual knockout
parasites. The self-resolving infection caused by double knockout parasites was
accompanied with a strong and long lasting protective immune response against
subsequent challenge with homologous and heterologous parasites. Previous
experiments conducted with Δpm4 parasites have indicated that antibodies
play a crucial role in the protection elicited in these experimental models28.In this paper, we utilized the available knowledge and properties of P.
berghei iRBCs sequestration and used the recent advances in in vivo
imaging technologies to visualize parasite distribution and load in different organs
of live mice infected with pbwt+ and Δmsp7+
parasites that express luciferase gene under the control of a schizont-specific
promoter (i.e., the ama-1). Imagings performed in experimentally induced
synchronous infections in mice were established by injection of 0.5 to
1×108 purified mature schizonts in four mice31. Collection of data at 21–23h after injection allowed the
visualization of sequesters parasites only in the lungs, adipose tissue and the
spleen2838. The luck of bioluminescence signal in the brain
could be due to several factors ranging from low level of parasites, below the
detection limit of the instruments, or to others factors such as putative
endothelial receptors expression, inflammatory markers and adhesins that became
up-regulated during infection. While blood parasitemia has been routinely used to
monitor disease progression, it is now recognized that measurements of total
parasite biomass in the whole body offer a better correlate of the disease status of
malariapatients. Bioluminescence analysis of complete mice or organs from different
animals during ongoing infections can be compared quantitatively and use to evaluate
parasites burden. Several recent studies have shown by in vivo imaging that the
timing of this iRBCs accumulation in the brain coincides with the development of ECM
and mice protected from cerebral complications do not show a similar increase of
iRBCs sequestration in the brain28384748. Anyway,
bioluminescence alone could not be use to define precisely the parasites burden in
some organs (i.e., brain) and further analysis are required. Parasites expressing
different fluorescent reporter proteins (e.g., GFP and mCherry) now offer the
possibility to provide an insight into the amounts of parasites (i.e., load) that
accumulate into the organs to understand malaria pathology by, for example, using
multiphoton microscopy.The enhanced virulence attenuation phenotype observed of Δpm4/Δmsp7
parasites bears crucial implications for the development of a malaria vaccine. The
lack of significant progress with subunit vaccines that contain only (parts of)
single proteins, together with an enhanced understanding of the protective immunity
to malaria has generated new interest in vaccines based on whole blood stage
parasite49. Sporozoites that have been attenuated either by
radiation or by genetic modification have shown promise as a whole parasite approach
to pre-erythrocytic vaccination505152535455. Recent studies
have demonstrated that the disruption of individual genes was not sufficient to
completely attenuate parasite virulence. Infection with p52-deficient sporozoites
protected mice against subsequent infectious sporozoite challenge, but the
immunizations led to sporozoite dose-dependent breakthrough infections5657. On the contrary sporozoites lacking both p52 and p36 exhibited
a complete growth arrest in the liver in vitro58. This study
now demonstrates that sequential disruption of specific blood-stage genes generates
blood-stage parasites with a progressively virulence-attenuated phenotype that are
capable of inducing protective immunity in the P. berghei model of malaria.
These observations provide a compelling case for generating additional genetically
attenuated blood stage (GABS) mutants for assessing their potential usefulness in
the development of GABS based humanmalaria vaccines.
Methods
Mice and parasites
Six- to eight-week-old female C57BL/6 were purchased from Charles River while
CD1, BALB/c and nude mice were purchased from Harlan Sprague. NOD/SCID (age
10–16 weeks) were kindly provided by Prof. Velardi and Prof. Falini.
All studies involving animals have been performed according to the D.L 27
January 1992, n. 116, Italian legislation. The parasite strain P. berghei
ANKA was used as a control for wild type parasite (pbwt) and for the generation
of the mutant lines Δmsp7 cl7 and Δmsp7 cl8. The msp7
gene (PBANKA_134910) has been disrupted by introducing the construct
pRSmsp7-tgdhfr/ts into the genome of pbwt parasites by double cross-over
recombination as described below. Clones Δmsp7 cl7 and Δmsp7 cl8
were obtained from two transfection experiments. Δmsp7+
is a mutant parasite line (Δmsp7 cl9) generated introducing construct
pRSmsp7-tgdhfr/ts into the genome of pbwt+ parasites by double
cross-over recombination. The parasite strain pbwt+ (1037cl1) is
a reference transgenic parasite line that expresses a fusion protein (GFP-Luc)
encompassing the GFP (mutant3) and the luciferase (LUC-IAV) coding sequence
under the control of the schizont-specific ama-1 promoter28. Δpm4/Δmsp7 cl4 and Δpm4/Δmsp7 cl12 are two
mutant parasite clones that are deficient in both pm4 and msp7
genes obtained by introducing pRSmsp7-hdhfr construct into the genome of
Δpm4 cl6 parasites line28 by double cross-over
recombination.
Generation and analysis of Δmsp7 and Δpm4/Δmsp7
parasite lines
The DNA plasmid pRSmsp7-tgdhfr/ts designed to target the msp7 locus of
P. berghei ANKA strain contains the following elements (Figure 1A): i) a 5′UTR 485 bp PCR fragments of the
msp7 gene (sense:
5′-CCGGGCCCGCGGGCTAGATTTAATCAGCAATTTGTC; ApaI site is
underline and antisense:
5′-CCATCGATTTTGTCTAAATATATGTGTGTGTATG; ClaI site is
underline); ii) a 3′UTR 375 bp PCR fragments (sense:
5′-GGAATTCATTATGTACACAGGAAATACATATAAAAC; EcoRI
site is underline and antisense:
5′-CGGGATCCCAATGTTACCGAAGAAAAATACAAAC; BamHI site is
underline); iii) the Toxoplasma gondii dihydrofolate
reductase/thymidylate synthase (tgdhfr/ts) selectable marker cassette.
The plasmid was linearised with SacII and used for the generation of
mutant lines Δmsp7 cl7, Δmsp7 cl8 and
Δmsp7+ as described below59. The
structure of the msp7 locus in transformed and wt parasites was analyzed
in PCR experiments (Figure 1B) using primer pair 1+2 (n.1:
5′-ATGATGGCATATAAAAAGTTA TGTTTTTTA G; n.2:
5′-TTATTTAAGATCAACTGTAGCTAAGG) under conditions where the msp7
sequence is readily amplified from pbwt (Figure 1B). The
expected integration into the msp7 locus was verified by successfully
amplifying the predicted 5′ and 3′ boundary sequences using
primer pairs 3+4 (n.3: 5′-ACTGGAGCAACATGCGGAC; n.4: 5′-
CAAACATACAAAAATAAACACC) and 5+6 (n.5: 5′- TATATAATTTGTGAGGGATATG; n.6:
5′-GTCGTATTCCCAATATTTACTAC) as shown in Figure
1B. For RT-PCR total RNA from mixed blood-stage parasites was
extracted using TRIzol reagent (Invitrogen) and treated with TURBO DNase
(Ambion). cDNA synthesis was performed using the Super script III Platinum
two-step qRT-PCR kit (Invitrogen). The amplification of msp7 gene was
performed with primer pair 1+2 (see Figure 1A) and as a
control the tubulin gene was amplified with the following primers: sense
5′-TGGAGCAGGAAATAACTGGG and antisense
5′-ACCTGACATAGCGGCTGAAA (Figure 1C and S1C). The
lack of MSP7 expression was confirmed by immunofluorescence experiments using
anti-PbMSP7 antibody raised in a mouse immunized with the recombinant protein.
For protein expression a region of the msp7 coding sequence was amplified
with the following primers: sense
5′-CACCATGATGGCATATAAAAAGTTATGTTTTTTAG and antisense
5′-TTATTTAAGATCAACTGTAGCTAAGG and cloned into pEXP1-DEST
Gateway® Invitrogen vector. Cell lines BL21 Star® pLysS
(Invitrogen) were transformed and the recombinant protein purified by Ni-NTA
Spin Kit (Qiagen) after IPTG (1mM) induction. Female BALB/c mice were immunized
four times with 50 μg of purified protein. The sera from immunized mice
was analyzed by immuno-microarray technology (data not shown) and used in
immunofluorescence assay at 1∶500 dilution. Antibody bound to the
blood-stage parasites was visualized following incubation with a secondary
antibody goat anti-mouse (FITC conjugated) (Figure 1D).
VECTASHIELD Mounting Medium with DAPI (Vector) Labs) was used to stain the
nuclei of parasites. The images were captured by Nikon Eclipse TE2000-U
microscopy and analyzed with NIS-Elements imaging software. The DNA plasmid
pRSpm7-hdhfr (Figure S1A), designed to target the msp7 locus in the
Δpm4 cl6 background parasites (that already contain the tgdhfr/ts
selectable marker used for the deletion of pm4 gene), was obtained from
plasmid pRSpm7-tgdhfr/ts by the exchange of tgdhfr/ts selectable marker
cassette with the humandihydrofolate reductase (hdhfr) selectable marker
cassette. The hdhfr cassette was obtained from plasmid pL0008 (MR4) by
PstI and EcoRI digestion and cloned into the plasmid
pRSpm7-tgdhfr/ts. The plasmid was linearized with SacII and used for the
generation of mutant lines Δpm4/Δmsp7 cl4 and
Δpm4/Δmsp7 cl12. The disruption of the msp7 locus by
plasmid pRSpm7-hdhfr in these parasites line was analyzed by PCR reaction using
primer pair 1+2 as describe above (Figure 1SB). Integration specific PCR was
performed to confirm plasmid insertion in the msp7 locus using primers
pair: 3+7 (n. 3 as above; n.7: 5′-AGCACAATATCTAGGATACTAC) to analyze
the 5′UTR integration site and primer pair 8+6 (n. 6 as above; n. 8:
5′-ATGGTTGGTTCGCTAAACTGCATCG) to investigate the 3′UTR
integration site (Figure S1B). For the generation of all mutant lines
blood-stages parasites were transfected with 5–10 µg of
gel-purified DNA linear fragments and mutant parasites were obtained by the
standard method of drug selection by pyrimethamine or WR92210 (kindly provided
by Jacobus Pharmaceutical Company) in mice59. We enriched the
recombinant genotype in the parental transfected parasites population after at
least four repeated drug selection treatments until no wild-type genotype was
detectable by genomic PCR. Resistant parasites were subsequently cloned by
limiting dilution as previously described59.
Monitoring of parasite infection
The course of infection in BALB/c mice, which are not susceptible to ECM, was
analyzed after either intraperitoneal (i.p) or intravenously (i.v) inoculations
of 107 or 50 infected red blood cells (iRBCs) respectively. The
parasitemia ( = % of infected erythrocytes) was determined by counting daily
Giemsa stained slides of tail blood. Challenge experiments were carried out by
i.v. injection of pbwt or P. yoelii 17X iRBCs.
Assessment of ECM
The development of cerebral complications was analyzed in C57BL/6 and CD1mice
that are susceptible to ECM. This condition in P. berghei is well
characterized and defined as the development of cerebral complications (drop in
body temperature <34°C, ataxia, paralysis, convulsions, coma) at
day 6–9 after infection of mice with 104 to
106 parasites237. In this study mice were
injected i.p. with 105 iRBCs (Δmsp7 and
Δpm4/Δmsp7 infected mice were also infected with higher dose
(106 to 107) because of the low growth rate of
parasites). The onset of cerebral complications was determined by observing
several clinical signs such as ruffled fur, hunching, limb paralysis, coma and
by measuring the drop in body temperature at day 5–8 after infection.
The body temperature was measured using a 2 Channel Thermometer TK 98802 (2
Biological Instruments) with a rectal probe for mice. A drop in temperature
below 34°C is indicative of cerebral complications36.For the analysis of blood-brain-barrier (BBB) damage and vascular permeability
C57BL/6 mice 7 days post infection had been injected i.v. with 2% Evans
Blue60. Two hours after dye injection the mice were perfused
with heparinized PBS. The brain were dissected, weighted, digital image
collected, frozen in LN2, and stored at −80°C.
Brain samples were homogenized in 1 mL of 50% trichloroacetic acid
and stored overnight at 4°C. The supernatant was obtained by
centrifugation at 21.000 g for 30 minutes. The
amount of Evans Blue dye was measured by a microplate reader (excitation
600 nm, emission 650 nm) and quantified according to a
standard curve. Results are expressed as ng of Evans Blue per mg of brain
tissue. Bioluminescence analysis and signal quantification from brain of C57BL/6
mice with asynchronous infection at day 7 post injection was performed after
extensive intracardiac perfusion of the animals with heparinized PBS by in
vivo Imaging System (IVIS 200, Xenogen) as described28.
Imaging data were analyzed using the programs LIVING IMAGE (Xenogen) and IGOR
PRO (WaveMetrics).
Analysis of parasite distribution in live animals and isolated
organs
Sequestration of schizonts in whole bodies of live CD1mice and isolated organs
was visualized through imaging of luciferase-expressing, transgenic parasites
with an intensified-charge-coupled device (I-CCD) photon counting video camera
of the in vivo Imaging System (IVIS200 Xenogen) as described3839. Sequestration patterns were monitored in mice with
synchronized infections of schizonts. Infections (1–3% parasitemia)
were established by injection of cultured, purified schizonts. Imaging was
performed between 17h and 23h after injection of schizonts. Imaging of
individual organs, obtained by dissection from animals at 21h, was done as
described previously38. Imaging data were analyzed by using the
programs LIVING IMAGE (Xenogen) and IGOR PRO (WaveMetrics).
Statistical analyses
Differences in survival of different groups were analysed using the Kaplan-Meier
log-rank test. Differences in the parasitemia and bioluminescence were performed
using the Mann-Whitney nonparametric test. For all statistical test,
p<0.05 was considered significant. In all figures, *, **, *** denote p
value of p<0.05, p<0.01 e p<0.001 respectively.
Author Contributions
RS, designed and performed research, analyzed data, wrote the paper; EA, SC, PA, BC,
performed research, analyzed data; MR, FB, intellectually contributed to the work;
MDC, TD, analyzed data; AC, designed research, analyzed data and wrote the
paper.
Authors: Dipak K Raj; Christian P Nixon; Christina E Nixon; Jeffrey D Dvorin; Christen G DiPetrillo; Sunthorn Pond-Tor; Hai-Wei Wu; Grant Jolly; Lauren Pischel; Ailin Lu; Ian C Michelow; Ling Cheng; Solomon Conteh; Emily A McDonald; Sabrina Absalon; Sarah E Holte; Jennifer F Friedman; Michal Fried; Patrick E Duffy; Jonathan D Kurtis Journal: Science Date: 2014-05-23 Impact factor: 47.728
Authors: Sylvie Briquet; Nadou Lawson-Hogban; Bertrand Boisson; Miguel P Soares; Roger Péronet; Leanna Smith; Robert Ménard; Michel Huerre; Salah Mécheri; Catherine Vaquero Journal: Infect Immun Date: 2015-04-27 Impact factor: 3.441
Authors: Peng Liu; Arthur H Robbins; Melissa R Marzahn; Scott H McClung; Charles A Yowell; Stanley M Stevens; John B Dame; Ben M Dunn Journal: PLoS One Date: 2015-10-28 Impact factor: 3.240
Authors: Barbara Capuccini; Jingwen Lin; Carlos Talavera-López; Shahid M Khan; Jan Sodenkamp; Roberta Spaccapelo; Jean Langhorne Journal: Sci Rep Date: 2016-12-19 Impact factor: 4.379